» Articles » PMID: 19621091

Feasibility of Onchocerciasis Elimination with Ivermectin Treatment in Endemic Foci in Africa: First Evidence from Studies in Mali and Senegal

Abstract

Background: Mass treatment with ivermectin is a proven strategy for controlling onchocerciasis as a public health problem, but it is not known if it can also interrupt transmission and eliminate the parasite in endemic foci in Africa where vectors are highly efficient. A longitudinal study was undertaken in three hyperendemic foci in Mali and Senegal with 15 to 17 years of annual or six-monthly ivermectin treatment in order to assess residual levels of infection and transmission and test whether ivermectin treatment could be safely stopped in the study areas.

Methodology/principal Findings: Skin snip surveys were undertaken in 126 villages, and 17,801 people were examined. The prevalence of microfilaridermia was <1% in all three foci. A total of 157,500 blackflies were collected and analyzed for the presence of Onchocerca volvulus larvae using a specific DNA probe, and vector infectivity rates were all below 0.5 infective flies per 1,000 flies. Except for a subsection of one focus, all infection and transmission indicators were below postulated thresholds for elimination. Treatment was therefore stopped in test areas of 5 to 8 villages in each focus. Evaluations 16 to 22 months after the last treatment in the test areas involved examination of 2,283 people using the skin snip method and a DEC patch test, and analysis of 123,000 black flies. No infected persons and no infected blackflies were detected in the test areas, and vector infectivity rates in other catching points were <0.2 infective flies per 1,000.

Conclusion/significance: This study has provided the first empirical evidence that elimination of onchocerciasis with ivermectin treatment is feasible in some endemic foci in Africa. Although further studies are needed to determine to what extent these findings can be extrapolated to other endemic areas in Africa, the principle of elimination has been established. The African Programme for Onchocerciasis Control has adopted an additional objective to assess progress towards elimination endpoints in all onchocerciasis control projects and to guide countries on cessation of treatment where feasible.

Citing Articles

The Impact of Onchocerciasis Elimination Measures in Africa: A Systematic Review.

Ncogo P, Giesen C, Perteguer M, Rebollo M, Nguema R, Benito A Trop Med Infect Dis. 2025; 10(1).

PMID: 39852658 PMC: 11768683. DOI: 10.3390/tropicalmed10010007.


Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials.

Nebangwa D, Shey R, Shadrack D, Shintouo C, Yaah N, Yengo B PLoS One. 2024; 19(10):e0312315.

PMID: 39432476 PMC: 11493244. DOI: 10.1371/journal.pone.0312315.


Persistent transmission of onchocerciasis in Kwanware-Ottou focus in Wenchi health district, Ghana.

Nditanchou R, Agyemang D, Dixon R, DSouza S, Selby R, Opare J BMC Infect Dis. 2024; 24(1):1156.

PMID: 39402497 PMC: 11475550. DOI: 10.1186/s12879-024-10071-2.


Effects of Five Years of Treatment of Onchocerciasis with Ivermectin under Community Guidelines in Resurgent Areas of Burkina Faso: A before-and-after Analysis.

Ouedraogo M, Meda I, Kourouma K, Wienne F, Nare D, Bougouma C Trop Med Infect Dis. 2024; 9(9).

PMID: 39330896 PMC: 11435634. DOI: 10.3390/tropicalmed9090207.


The Interruption of Transmission of Onchocerciasis in Abia, Anambra, Enugu, and Imo States, Nigeria: The Largest Global Onchocerciasis Stop-Treatment Decision to Date.

Ityonzughul C, Sallau A, Miri E, Emukah E, Kahansim B, Adelamo S Pathogens. 2024; 13(8).

PMID: 39204271 PMC: 11356909. DOI: 10.3390/pathogens13080671.


References
1.
Remme J, Ba O, Dadzie K, Karam M . A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull World Health Organ. 1986; 64(5):667-81. PMC: 2490951. View

2.
De Sole G, Baker R, Dadzie K, Giese J, Guillet P, Keita F . Onchocerciasis distribution and severity in five West African countries. Bull World Health Organ. 1991; 69(6):689-98. PMC: 2393320. View

3.
De Sole G, Remme J, Awadzi K, Accorsi S, Alley E, Ba O . Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ. 1989; 67(6):707-19. PMC: 2491300. View

4.
Yameogo L, Toe L, Hougard J, Boatin B, Unnasch T . Pool screen polymerase chain reaction for estimating the prevalence of Onchocerca volvulus infection in Simulium damnosum sensu lato: results of a field trial in an area subject to successful vector control. Am J Trop Med Hyg. 1999; 60(1):124-8. DOI: 10.4269/ajtmh.1999.60.124. View

5.
Borsboom G, Boatin B, Nagelkerke N, Agoua H, Akpoboua K, Alley E . Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. 2003; 2(1):8. PMC: 156613. DOI: 10.1186/1475-2883-2-8. View